SCHEMBL5541283

SCHEMBL5541283

O=C(OCc1ccc(OC(F)(F)F)cc1)N1CCN(CCN2CCC3(CC2)Cn2cc([N+](=O)[O-])nc2O3)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.53
CHRM1 P11229 1/20 0.48
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
ENPP2 Q13822 8/20 0.42
ATXN2 Q99700 6/20 0.42
HRH2 P25021 1/20 0.39
HRH1 P35367 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DGAT2 Q96PD7 1/20 0.37
CA2 P00918 2/20 0.36
P2RY1 P47900 1/20 0.36
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
PGGT1B P53609 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545671 0.92 KCNH2 (0.51) KCNH2CHRM1PTGS1SLC6A2SLC6A4
SCHEMBL5543065 0.91 ENPP2 (0.42) KCNH2CHRM1PTGS1SLC6A2SLC6A4
SCHEMBL5539718 0.88 ENPP2 (0.40) KCNH2CHRM1ENPP2ATXN2HRH2
SCHEMBL5546090 0.87 CA1 (0.38) KCNH2ENPP2ATXN2HRH2HRH1
SCHEMBL6010965 0.85 KCNH2 (0.64) KCNH2CHRM1PTGS1SLC6A2SLC6A4
SCHEMBL5542691 0.84 ENPP2 (0.47) KCNH2CHRM1PTGS1SLC6A2SLC6A4
SCHEMBL5542853 0.83 ENPP2 (0.44) KCNH2CHRM1PTGS1SLC6A2SLC6A4
SCHEMBL5542799 0.83 ENPP2 (0.42) KCNH2CHRM1PTGS1SLC6A2SLC6A4
SCHEMBL6425174 0.81 MEN1 (0.44) KCNH2ENPP2ATXN2ALDH1A1SMN1; SMN2
SCHEMBL5546698 0.80 KCNH2 (0.54) KCNH2CHRM1PTGS1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885CHRM1 463/4885PTGS1 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.